Campbell & Co Investment Adviser’s Revance Therapeutics, Inc. RVNC Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,907	Closed	-$1.16M	–	1399
2023 Q3	$1.16M	Buy	100,907 +85,074	+537%	+$1.64M	0.14%	222
2023 Q2	$401K	Buy	+15,833	New	+$493K	0.07%	529
2023 Q1	–	Sell	-28,390	Closed	-$524K	–	1073
2022 Q4	$524K	Buy	+28,390	New	+$649K	0.13%	287
2021 Q3	–	Sell	-12,600	Closed	-$373K	–	815
2021 Q2	$373K	Buy	+12,600	New	+$363K	0.15%	244
2019 Q2	–	Sell	-10,776	Closed	-$170K	–	738
2019 Q1	$170K	Buy	+10,776	New	+$187K	0.08%	467

Other funds holding RVNC

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Campbell & Co Investment Adviser's RVNC Position: Q4 2023 in Review

Campbell & Co Investment Adviser sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2023, closing a stake of 100,907 shares — an estimated $1.16M sold.

Campbell & Co Investment Adviser first reported a position in RVNC in Q1 2019 and held it in 5 quarters. The position peaked at $1.16M in Q3 2023. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2023.

Campbell & Co Investment Adviser reported no remaining Revance Therapeutics, Inc. position as of Q4 2023 after selling out during the quarter.
Campbell & Co Investment Adviser sold 100,907 Revance Therapeutics, Inc. shares in Q4 2023, an estimated $1.16M.
Campbell & Co Investment Adviser first reported a position in Revance Therapeutics, Inc. in Q1 2019 and held it in 5 quarters.
Campbell & Co Investment Adviser's Revance Therapeutics, Inc. position peaked at $1.16M in Q3 2023.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2023.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2023, filed 13 Feb 2024.